TREATMENT OF HEART FAILURE IN WOMEN
A method is disclosed utilizing an androgen such as testosterone and/or a selective androgen receptor modulator for treating or delaying the further development of heart failure, and other disorders in females including manifestations of heart failure and concomitant cardiovascular and noncardiovascular disorders.
1 . A method for treating heart failure or for slowing or ceasing the progression of heart failure in a human female, which comprises administering to said female having heart failure a pharmaceutically effective amount of an androgen.
2 . A method for treating heart failure or for slowing or ceasing the progression of heart failure in a human female, which comprises administering to said female having heart failure a pharmaceutically effective amount of a selective androgen receptor modulator.
3 . The method of claim 1 , wherein said androgen is testosterone, dihydrotestosterone (DHT), androstenedione, or methyl testosterone.
4 . The method of claim 3 , wherein said androgen is testosterone.
5 . The method of claim 4 , wherein said testosterone is administered in an amount that provides a testosterone serum level concentration of from approximately 2 ng/dL to approximately 2000 ng/dL.
6 . The method of claim 5 , wherein said testosterone is administered in an amount that provides a testosterone serum level concentration of from approximately 10 ng/dL to approximately 500 ng/dL.
7 . The method of claim 6 , wherein said testosterone is administered in an amount that provides a testosterone serum level concentration of from approximately 15 ng/dL to approximately 200 ng/dL.
8 . The method of claim 5 , where said testosterone is administered using a transdermal patch comprising a polymer matrix and said testosterone.
9 . The method of claim 8 , wherein said patch provides an amount of testosterone of approximately 300 mcg/day.
10 . The method of claim 8 , wherein said patch comprises approximately 8.4 mg of testosterone.
11 . The method of claim 1 , wherein said heart failure is associated with any of ACA/AHA Stages B, C or D.
12 . A method for improving coronary artery disease, hypertension, dilated cardiomyopathy, valvular heart disease, endothelial function or a disorder of the left ventricle, pericardium, myocardium, endocardium or great vessels in a human female, which comprises administering to said female a pharmaceutically effective amount of an androgen, wherein said human female has heart failure.
13 . The method of claim 12 , wherein said method is for improving coronary artery disease, hypertension or dilated cardiomyopathy.
14 . A method for improving insulin resistance or diabetes in a human female, which comprises administering to said female a pharmaceutically effective amount of an androgen and/or a selective androgen receptor modulator, wherein said human female has heart failure.
15 . A method for improving exercise tolerance or NYHA heart failure classification in a human female, which comprises administering to said female a therapeutically effective amount of an androgen and/or a selective androgen receptor modulator, wherein said human female has heart failure.
16 . The method of claim 15 , wherein said androgen is testosterone.
17 . A method for treating heart failure or for slowing or ceasing the progression of heart failure in a human female having one or more structural heart changes, which comprises administering to said female having said one or more structural heart changes a pharmaceutically effective amount of an androgen.
18 . The method of claim 17 , wherein said androgen is testosterone.
19 . A method for treating heart failure or for slowing or ceasing the progression of heart failure in a human female having one or more structural heart changes, which comprises administering to said female having said one or more structural heart changes a pharmaceutically effective amount of testosterone, wherein said testosterone is administered in an amount that provides a testosterone serum level concentration of from approximately 80 ng/dL to approximately 100 ng/dL.
20 . A method for treating heart failure or for slowing or ceasing the progression of heart failure in a human female, which comprises administering to said female having heart failure a pharmaceutically effective amount of an androgen and a selective androgen receptor modulator.
21 . The method of claim 20 , wherein said androgen and selective androgen receptor modulator are administered in an amount that provides a therapeutic equivalence to a testosterone serum level concentration of from approximately 2 ng/dL to approximately 2000 ng/dL.